AbbVie delivered a beat-and-raise third quarter driven by immunology and a strengthening neuroscience franchise, reinforcing its ability to keep shareholder momentum while management considers future M&A. CEO Rob Michael said the company has capacity for additional acquisitions but prefers “bolt-on transactions” rather than another megadeal like the 2020 Allergan acquisition. Financially, AbbVie reported Q3 sales of $17.4 billion and EPS of $3.82, both above consensus, and raised full-year EPS guidance. Immunology revenues hit $9.17 billion, led by Skyrizi and Rinvoq—Skyrizi grew 23% to $5.7 billion in the quarter and AbbVie lifted its full-year Skyrizi projection to $21.8 billion. On neuroscience, the company highlighted 19% year-over-year growth to $3.4 billion in Q3, including Vraylar exceeding $1 billion with 14% growth and additional contributions from Vyalev, Qulipta, and Ubrelvy. The earnings update ties together clinical-brand strength with a capital-allocation signal: investors are likely to interpret the acquisition posture as a search for assets that complement immunology and neuroscience rather than reset the company’s focus.